A rare case of multicentric castleman's disease transforms into multiple myeloma and its successful treatment

• Published in: Cancer biology & therapy 2018-11, Vol.19 (11), p.949-952
• Main Authors: Yang, Dan, Zhou, Xuan, Zhao, Youcai, Cao, Shibin, Su, Ailing, Zhang, Xuezhong, Xu, Yanli, Zhang, Xiuqun
• Format: Article
• Language: English
• Subjects: Castleman disease; Letter to the Editor; lymphoproliferative disorder; multiple myeloma; plasmocyte; thalidomide
• ISSN: 1538-4047; 1555-8576
• DOI: 10.1080/15384047.2018.1456606

Multicentric Castleman's disease (MCD) is a rare kind of lymphoproliferative disorder characterized by systemic problems such as frequent fever, fatigue and weight loss with angiofollicular lymph node hyperplasia. However, unlike unicentric Castleman's disease (UCD) with long-time survival by surgery and local radiotherapy, MCD remains poor prognosis due to no well-defined optimal treatment strategies and high risk of developing malignances especially lymphoma. We reported a case of MCD who received chemotherapy by ECHOP with unsatisfactory outcome and then oral administration with thalidomide combined with prednisone without disease progression after therapy. After 3 y, his MCD turned into multiple myeloma (MM) and accompanied by obvious response to combination of thalidomide with prednisone. Nowadays, there is no standard of therapy yet established for MCD. We successfully treated one such patient and found thalidomide based therapy may have a significant effect on MCD. We also proposed further researches with therapeutic potential about thalidomide for MCD.